Clinical issues in antibody design.
Antibody genes can now be cloned and expressed in various ways to give new versions of antibodies that possess reduced immunogenicity, improved affinity, altered size, increased avidity and novel effector functions. The task for any clinical application is, first, to define a relevant target, and then to design the optimal antibody-based therapeutic molecule to react with that target. This article reviews these improved antibody-based molecules and examines their role in cancer therapy.
Chester
K A
KA
Department of Clinical Oncology, Royal Free Hospital School of Medicine, London, UK.
Hawkins
R E
RE
D000818:Animals; D000906:Antibodies / Q000235:genetics / Q000627:therapeutic use*; D001709:Biotechnology / Q000639:trends; D003602:Cytotoxicity, Immunologic; D015316:Genetic Therapy; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000628:therapy*; D015202:Protein Engineering
D000906:Antibodies